Mirabegron Reduces Urinary Frequency and Improves Overactive Bladder Symptoms at 3 Months After 125I-brachytherapy for Prostate Cancer: An Open-Labeled, Randomized, Non–Placebo-Controlled Study-Reference-Cited by-同舟云学术

Mirabegron Reduces Urinary Frequency and Improves Overactive Bladder Symptoms at 3 Months After 125I-brachytherapy for Prostate Cancer: An Open-Labeled, Randomized, Non–Placebo-Controlled Study

Published:2021-12 Issue: Volume: Page:
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Nakai Yasushi,Tanaka Nobumichi^ORCID,Asakawa Isao,Miyake Makito^ORCID,Anai Satoshi,Torimoto Kazumasa^ORCID,Yamaki Kaori,Fujii Tomomi,Hasegawa Masatoshi,Fujimoto Kiyohide

Publisher

Elsevier BV

Subject

Urology

Reference26 articles.

1. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group;Grimm;BJU Int,2012

2. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?;Kuban;Int J Radiat Oncol Biol Phys,2011

3. Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer;Tanaka;BMC Cancer,2017

4. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

5. Urinary morbidity after 125I brachytherapy of the prostate;Mallick;BJU int,2003

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Duration of α-1 adrenergic antagonist administration after low-dose-rate brachytherapy for prostate cancer;Japanese Journal of Clinical Oncology;2024-08-28

2. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

3. Impact of Overactive Bladder on Quality of Life for Cancer Survivors;Current Bladder Dysfunction Reports;2023-08-24

4. Literature review on the efficacy of treatments for urinary incontinence in irradiated vs. non-radiated men treated for prostate cancer;AME Medical Journal;2022-09